ENTA Enanta Pharmaceuticals, Inc.

30.36
-0.38  -1%
Previous Close 30.74
Open 30.85
Price To book 2.20
Market Cap 579.36M
Shares 19,083,000
Volume 160,996
Short Ratio 7.35
Av. Daily Volume 180,038

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to commence 4Q 2017.
EDP-305
Primary biliary cholangitis (PBC)
Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Phase 2b ongoing. Data released November 2015. Phase 3 initiated
ABT-493
HCV
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved July 25, 2017.
VIEKIRA PAK - once-daily, fixed-dose formulation through Abbvie
HCV - genotype

Latest News

  1. Top 4 Pharmaceutical Stocks for 2017
  2. CORRECTING and REPLACING Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017
  3. Edited Transcript of ENTA earnings conference call or presentation 8-May-17 8:30pm GMT
  4. Enanta Pharmaceuticals reports 2Q loss
  5. Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017
  6. Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call
  7. Enanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients
  8. Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
  9. Enanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)
  10. AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis
  11. Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017
  12. Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2017
  13. Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : April 6, 2017
  14. Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2017
  15. Enanta Pharmaceuticals to Present at the H.C. Wainwright 1st Annual NASH Investor Conference
  16. [$$] Rare Discovery: A Value in the Biotech World
  17. Enanta Announces Japanese Ministry of Health, Labour and Welfare Grants Priority Review for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
  18. AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
  19. Enanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment Option with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C
  20. AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C